MRI and prostate cancer: A paradigm shift;L'IRM du cancer de la prostate: Un changement de paradigme

Journal de Radiologie

Volumn 89, Issue 9 C1, 2008, Pages 1053-1064

  Lemaitre, L ^a   Rouviere O ^b   Penna Renard, R ^c   Villers, A ^a   Puech, P ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cancer; Diagnosis; MRI; Prostate

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTIFACT; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL PROTOCOL; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; FOLLOW UP; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REPRODUCIBILITY; REVIEW; STANDARDIZATION; THREE DIMENSIONAL IMAGING; TREATMENT PLANNING; TUMOR RECURRENCE;

EID: 51049093584     PISSN: 02210363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0221-0363(08)73909-X     Document Type: Short Survey

References (98)

1. D'Amico AV, Whittington R, Malkowicz B, Schnall M, Schultz D, Cote K, et al. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol 2000;164:759-63.
2. Jager GJ, Severens JL, Thornbury JR, de La Rosette JJ, Ruijs SH, Barentsz JO. Prostate cancer staging: should MR imaging be used? - A decision analytic approach. Radiology 2000;215:445-51.
3. Engelbrecht MR, Jager GJ, Severens JL. Patient selection for magnetic resonance imaging of prostate cancer. Eur Urol 2001;40:300-7.
4. May F, Treumann T, Dettmar P, Hartung R, Breul J. Limited value of endorectal magnetic resonance imaging and transrectal ultrasonography in the staging of clinically localized prostate cancer. BJU Int 2001;87:66-9.
5. Rouviere O, Raudrant A, Ecochard R, Colin-Pangaud C, Pasquiou C, Bouvier R, et al. Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur Radiol 2003;13:931-42.
6. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006;176:2432-7.
7. Futterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241:449-58.
8. Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am 2000;38:115-38.
9. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 1999;213:473-80.
10. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: The clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007;25:146-52.
11. Kumar V, Jagannathan NR, Kumar R, Thulkar S, Gupta SD, Dwivedi SN, et al. Apparent diffusion coefficient of the prostate in men prior to biopsy: determination of a cut-off value to predict malignancy of the peripheral zone. NMR Biomed 2007;20:505-11.
12. Reinsberg SA, Payne GS, Riches SF, Ashley S, Brewster JM, Morgan VA, et al. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. AJR Am J Roentgenol 2007;188:91-8.
13. Girouin N, Mege-Lechevallier F, Tonina Senes A, Bissery A, Rabilloud M, Marechal JM, et al. Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 2007;17:1498-509.
14. Cornud F, Dana A, Portalez D. L'IRM de la prostate sans antenne endorectale : une nouvelle exception française ? J Radiol 2008;89:191-2.
15. Kirkham AP, Emberton M, Hoh IM, Illing RO, Freeman AA, Allen C. MR Imaging of Prostate after Treatment with High-Intensity Focused Ultrasound. Radiology 2008;246:833-44.
16. Li H, Sugimura K, Kaji Y, Kitamura Y, Fujii M, Hara I, et al. Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. AJR Am J Roentgenol 2006;186:729-42.
17. Kim CK, Park BK, Han JJ, Kang TW, Lee HM. Diffusion-weighted imaging of the prostate at 3 T for differentiation of malignant and benign tissue in transition and peripheral zones: preliminary results. J Comput Assist Tomogr 2007;31:449-54.
18. Park BK, Kim B, Kim CK, Lee HM, Kwon GY. Comparison of phased-array 3.0-T and endorectal 1.5-T magnetic resonance imaging in the evaluation of local staging accuracy for prostate cancer. J Comput Assist Tomogr 2007;31:534-8.
19. Wang L, Hricak H, Kattan MW, Chen HN, Kuroiwa K, Eisenberg HF, et al. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology 2007;242:182-8.
20. Cornud F, Bellin MF, Portalez D. IRM et bilan d'extension du cancer de la prostate. J Radiol 2006;87:228-45.
21. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;243:28-53.
22. Rouviere O, Hartman RP, Lyon net D. Prostate MR imaging at high-field strength: evolution or revolution? Eur Radiol 2006;16:276-84.
23. Sung MT, Lin H, Koch MO, Davidson DD, Cheng L. Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer. Am J Surg Pathol 2007;31:311-8.
24. Epstein JI. Radial distance of extraprostatic extension measured by an ocular micrometer is an independent predictor of prostate-specific antigen recurrence: a new proposal for the substaging of pT3a prostate cancer. Am J Surg Pathol 2008;32:337-8.
25. Wheeler TM, Dillioglugil O, Kattan MW, Arakawa A, Soh S, Suyama K, et al. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Human pathology 1998;29:856-62.
26. Srigley JR. Key issues in handling and reporting radical prostatectomy specimens. Arch Pathol Lab Med 2006;130303-17.
27. McKenna DA, Coakley FV, Westphalen AC, Zhao S, Lu Y, Webb EM, et al. Prostate Cancer: Role of Pretreatment MR in Predicting Outcome after External-Beam Radiation Therapy-Initial Experience. Radiology 2008;247:141-6.
28. Cheng L, Koch MO, Juliar BE, Daggy JK, Foster RS, Bihrle R, et al. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J Clin Oncol 2005;23:2911-7.
29. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986;1:60-3.
30. McNeal JE, Haillot O. Patterns of spread of adenocarcinoma in the prostate as related to cancer volume. The Prostate 2001;49:48-57.
31. Chun FK, Briganti A, Jeldres C, Gallina A, Erbersdobler A, Schlomm T, et al. Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. Eur J Cancer 2007;43:536-43.
32. Secin FP, Serio A, Bianco FJ, Jr., Karanikolas NT, Kuroiwa K, Vickers A, et al. Preoperative and intraoperative risk factors for side-specific positive surgical margins in laparoscopic radical prostatectomy for prostate cancer. Eur Urol 2007;51:764-71.
33. van den Ouden D, Hop WC, Schroder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998;160:1392-7.
34. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005;95:751-6.
35. Masterson TA, Pettus JA, Middleton RG, Stephenson RA. Isolated seminal vesicle invasion imparts better outcomes after radical retropubic prostatectomy for clinically localized prostate cancer: prognostic stratification of pt3b disease by nodal and margin status. Urology 2005;66:152-5.
36. Van Poppel H, Vekemans K, Da Pozzo L, Bono A, Kliment J, Montironi R, et al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer 2006;42:1062-7.
37. D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D, et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001;166:2185-8.
38. D'Amico AV, Tempany CM, Cormack R, Hata N, Jinzaki M, Tuncali K, et al. Transperineal magnetic resonance image guided prostate biopsy. J Urol 2000;164:385-7.
39. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297-301.
40. Jager GJ, Ruijter ET, van de Kaa CA, de la Rosette JJ, Oosterhof GO, Thornbury JR, et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol 1996;166:845-52.
41. Kabalin JN, McNeal JE, Price HM, Freiha FS, Stamey TA. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol 1989;141:1091-4.
42. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990;66:1225-33.
43. Khatami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007;120:170-4.
44. Tenke P, Horti J, Balint P, Kovacs B. Prostate cancer screening. Recent Results Cancer Res. 2007;175:65-81.
45. Kikuchi E, Scardino PT, Wheeler TM, Slawin KM, Ohori M. Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol 2004;172:508-11.
46. Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D'Amico AV. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. Cancer 1998;83:748-52.
47. Cheng L, Jones TD, Pan CX, Barbarin A, Eble JN, Koch MO. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 2005;18:1022-6.
48. Villers A, Puech P, Leroy X, Biserte J, Fantoni JC, Lemaitre L. Dynamic Contrast-Enhanced MRI for Preoperative Identification of Localised Prostate Cancer. European Urology supplements 2007; 6:525-32.
49. Singh AK, Kruecker J, Xu S, Glossop N, Guion P, Ullman K, et al. Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int 2008;101:841-5.
50. Gosselaar C, Roobol MJ, Roemeling S, Wolters T, van Leenders GJ, Schroder FH. The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer. BJU Int 2008;101:685-90.
51. Ikonen S, Kivisaari L, Tervahartiala P, Vehmas T, Taari K, Rannikko S. Prostatic MR imaging. Accuracy in differentiating cancer from other prostatic disorders. Acta Radiol 2001;42:348-54.
52. Coakley FV, Kurhanewicz J, Lu Y, Jones KD, Swanson MG, Chang SD, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002;223:91-7.
53. Dhingsa R, Qayyum A, Coakley FV, Lu Y, Jones KD, Swanson MG, et al. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology 2004;230:215-20.
54. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005;234:804-14.
55. Kim JK, Hong SS, Choi YJ, Park SH, Ahn H, Kim CS, et al. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging 2005;22:639-46.
56. Puech P, Potiron E, Lemaitre L, Leroy C, Biserte J, Villers A. Diagnostic accuracy of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in the identification of localized prostate cancer: Correlation with radical prostatectomy findings (soumis). Eur Urol 2008.
57. Mazaheri Y, Shukla-Dave A, Hricak H, Fine SW, Zhang J, Inurrigarro G, et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging-correlation with pathologic findings. Radiology 2008;246:480-8.
58. Kozlowski P, Chang SD, Goldenberg SL. Diffusion-weighted MRI in prostate cancer - comparison between single-shot fast spin echo and echo planar imaging sequences. Magn Reson Imaging 2008;26:72-6.
59. Kumar V, Jagannathan NR, Kumar R, Das SC, Jindal L, Thulkar S, et al. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Magn Reson Imaging 2006;24:541-8.
60. Naughton CK, Ornstein DK, Smith DS, Catalona WJ. Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores. J Urol 2000;163:168-71.
61. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142:71-4; discussion 4-5.
62. Norberg M, Egevad L, Holmberg L, Sparen P, Norlen BJ, Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 1997;50:562-6.
63. Presti JC, Jr., O'Dowd GJ, Miller MC, Mattu R, Veltri RW. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol 2003;169:125-9.
64. Mian BM, Naya Y, Okihara K, Vakar-Lopez F, Troncoso P, Babaian RJ. Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. Urology 2002;60:836-40.
65. Villers A, Mouton D, Rebillard X, Chautard D, Ruffion A, Staerman F, et al. Biopsy technique and biopsy schemes for a first series of prostatic biopsies. Prog Urol 2004;14:144-53.
66. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007;52:1309-22.
67. Stewart RJ, Panigrahy D, Flynn E, Folkman J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001;165:688-93.
68. Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate - a 4-year experience. Urology 2007;70:27-35.
69. Lemaitre L, Puech P, Poncelet E, Bouyé S, Leroy X, Biserte J, et al. Dynamic Contrast Enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings (accepté). Eur Radiol. 2008.
70. Ben Cheikh Aec. (soumis). Eur Radiol. 2008.
71. Anastasiadis AG, Lichy MP, Nagele U, Kuczyk MA, Merseburger AS, Hennenlotter J, et al. MRI-Guided Biopsy of the Prostate Increases Diagnostic Performance in Men with Elevated or Increasing PSA Levels after Previous Negative TRUS Biopsies. Eur Urol 2006;50:738-48.
72. Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Current opinion in urology. 2008;18:71-7.
73. Xu S, Kruecker J, Guion P, Glossop N, Neeman Z, Choyke P, et al. Closed-loop control in fused MR-TRUS image-guided prostate biopsy. Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv 2007;10:128-35.
74. Puech P, Villers A, Mouton D, Leroy X, Lemaitre L. Cancer de la prostate : les aspects cliniques, biologiques et histopathologiques utiles au radiologue. J Radiol 2006;87:189-200.
75. Grenier N, Trillaud H, Palussière J, Mougenot C, Quesson B, Denis De Senneville B, Moonen C. Thérapie par ultras-sons focalisés. J Radiol 2007;88:1787-800.
76. Rouviere O, Souchon R, Salomir R, Gelet A, Chapelon JY, Lyonnet D. Transrectal high-intensity focused ultrasound ablation of prostate cancer: effective treatment requiring accurate imaging. Eur J Radiol 2007;63:317-27.
77. Nguyen PL, D'Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 2007;110:1417-28.
78. Gelet A, Chapelon JY, Poissonnier L, Bouvier R, Rouviere O, Curiel L, et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004;63:625-9.
79. Poissonnier L, Chapelon JY, Rouviere O, Curiel L, Bouvier R, Martin X, et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol. 2007 Feb; 51(2):381-7.
80. Nudell DM, Wefer AE, Hricak H, Carroll PR. Imaging for recurrent prostate cancer. Radiol Clin North Am 2000;38:213-29.
81. Rouviere O, Valette O, Grivolat S, Colin-Pangaud C, Bouvier R, Chapelon JY, et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor - correlation with biopsy findings. Urology 2004;63:922-7.
82. Pucar D, Shukla-Dave A, Hricak H, Moskowitz CS, Kuroiwa K, Olgac S, et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapyinitial experience. Radiology 2005;236:545-53.
83. Ben Cheikh A, Girouin N, Ryon-Taponnier P, Mège-Lechevallier F, Gelet A, Chapelon JY, et al. Détection par IRM des récidives locales du cancer de prostate après traitement par ultrasons focalisés de haute intensité transrectaux: étude préliminaire J Radiol 2008;89:571-7.
84. Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, van Lier HJ, Barentsz JO. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 2002;12:2294-302.
85. Yu KK, Hricak H, Alagappan R, Chernoff DM, Bacchetti P, Zaloudek CJ. Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology 1997;202:697-702.
86. Futterer JJ, Engelbrecht MR, Jager GJ, Hartman RP, King BF, Hulsbergen-Van de Kaa CA, et al. Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils : Local staging accuracy of prostate cancer using endorectal coil MR imaging. Eur Radiol 2007;17:1055-65.
87. Heijmink SW, Futterer JJ, Hambrock T, Takahashi S, Scheenen TW, Huisman HJ, et al. Prostate Cancer: Body-Array versus Endorectal Coil MR Imaging at 3 T-Comparison of image quality, localization, and staging performance. Radiology 2007;244:184-95.
88. Qayyum A, Coakley FV, Lu Y, Olpin JD, Wu L, Yeh BM, et al. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 2004;183:1079-83.
89. Kirkham AP, Emberton M, Allen C. How Good is MRI at Detecting and Characterising Cancer within the Prostate? Eur Urol 2006;50:1163-75.
90. Futterer JJ, Engelbrecht MR, Huisman HJ, Jager GJ, Hulsbergen-van De Kaa CA, Witjes JA, et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 2005;237: 541-9.
91. Mullerad M, Hricak H, Wang L, Chen HN, Kattan MW, Scardino PT. Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology 2004;232:140-6.
92. Sexton T, Rodrigues G, Brecevic E, Boyce L, Parrack D, Lock M, et al. Controversies in prostate cancer staging implementation at a tertiary cancer center. Can J Urol 2006;13:3327-34.
93. Warren RM, Pointon L, Thompson D, Hoff R, Gilbert FJ, Padhani A, et al. Reading protocol for dynamic contrast-enhanced MR images of the breast: sensitivity and specificity analysis. Radiology 2005;236:779-88.
94. Warren RM, Thompson D, Pointon LJ, Hoff R, Gilbert FJ, Padhani AR, et al. Evaluation of a prospective scoring system designed for a multicenter breast MR imaging screening study. Radiology 2006;239:677-85.
95. Jung JA, Coakley FV, Vigneron DB, Swanson MG, Qayyum A, Weinberg V, et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004;233:701-8.
96. Puech P, Betrouni N, Viard R, Villers A, Leroy X, Lemaitre L, editors. Prostate cancer computer-assisted diagnosis software using dynamic contrast-enhanced MRI. Engineering in Medicine and Biology Society, 2007 EMBS 2007 29th Annual International Conference of the IEEE; 2007.
97. Westphalen AC, Coakley FV, Qayyum A, Swanson M, Simko JP, Lu Y, et al. Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. Radiology 2008;246:177-84.
98. Jung DC, Lee HJ, Kim SH, Choe GY, Lee SE. Preoperative MR imaging in the evaluation of seminal vesicle invasion in prostate cancer: Pattern analysis of seminal vesicle lesions. J Magn Reson Imaging 2008;28:144-150.